Clinical Trial

Investigating the Effect of Obicetrapib on Lipoprotein Metabolism

Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated September 19, 2024 (before its estimated September 26, 2024 completion). Its status may not reflect the trial's current state.
Summary
To determine the treatment effect with obicetrapib (10 mg) on the fractional catabolic rate (FCR) of apolipoprotein (apo) B100 in low-density lipoprotein (LDL).
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2023-07-25; most recent amendment 2024-09-14.
Status change: Recruiting → Active, Not Recruiting 2024-08-12
Status change: Not Yet Recruiting → Recruiting 2024-01-20
Trial Details
NCT Number NCT05972278
Lead Sponsor NewAmsterdam Pharma
Collaborators: University of Pennsylvania
Conditions Lipid Metabolism
Enrollment 22 participants
Start Date 2023-12-01
Primary Completion 2024-09-26 (estimated)
Study Completion 2024-10-14 (estimated)
Updated on ClinicalTrials.gov 2024-09-19